Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity: 2012-2025

Historic Liabilities and Shareholders Equity for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $280.7 million.

  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity fell 25.47% to $280.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 22.51%. This contributed to the annual value of $280.7 million for FY2025, which is 25.47% down from last year.
  • As of FY2025, Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $280.7 million, which was down 25.47% from $376.7 million recorded in FY2024.
  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $462.3 million during FY2023, with a 5-year trough of $280.7 million in FY2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $376.7 million (2024), whereas its average is $373.2 million.
  • In the last 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity rose by 23.14% in 2023 and then decreased by 25.47% in 2025.
  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $438.8 million in 2021, then dropped by 14.44% to $375.4 million in 2022, then climbed by 23.14% to $462.3 million in 2023, then decreased by 18.52% to $376.7 million in 2024, then declined by 25.47% to $280.7 million in 2025.